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Summary  Patients  with  coronary  artery  disease  and  a  history  of  stroke  account  for  as  many  as
one in  eight  of  all  patients  with  coronary  artery  disease,  and  they  are  at  higher  risk  of  ischaemic
events than  patients  with  ‘lone’  coronary  artery  disease.  It  is  therefore  tempting  to  increase
the potency  of  antithrombotic  treatment  in  this  patient  subset.  However,  these  patients  are
also at  greater  risk  of  intracranial  haemorrhage.  In  recent  trials  of  new  antithrombotic  agents
in acute  coronary  syndromes,  patients  with  a  history  of  cerebrovascular  disease  derived  no
clinical beneﬁt  from  (and  were  even  harmed  by)  the  potent  novel  antithrombotic  agents,  with
an increased  risk  of  intracranial  haemorrhage.  However,  this  risk  did  not  appear  to  be  uniform:  it
was higher  in  patients  with  a  history  of  stroke  than  in  those  with  a  history  of  transient  ischaemic
attack, and  appeared  to  be  largely  conﬁned  to  the  ﬁrst  year  after  stroke/transient  ischaemic
attack. Speciﬁc  strategies  to  optimize  the  beneﬁt/risk  ratio  of  antithrombotic  agents  in  this
relatively common  patient  group  should  be  developed  and  evaluated.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.Abbreviations: ACS, Acute coronary syndrome; CAD, Coronary artery disease; CI, Conﬁdence interval; HR, Hazard ratio; ICH, Intracranial
aemorrhage; TIA, Transient ischaemic attack; TIMI, Thrombolysis in myocardial infarction.
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Résumé  Les  patients  coronariens  avec  un  antécédent  d’AVC  ou  d’AIT  représentent  1/8e des
patients coronariens  et  ont  un  risque  d’événement  ischémique  majoré.  Il  serait  donc  ten-
tant d’augmenter  l’intensité  du  traitement  antithrombotique  chez  ces  patients  ;  toutefois,
ils présentent  également  un  risque  majoré  d’hémorragie  intracranienne.  Dans  plusieurs  études
récentes  évaluant  de  nouveaux  traitements  antithrombotiques  chez  les  patients  présentant
un syndrome  coronaire  aigu,  les  patients  avec  un  antécédent  de  maladie  cérébrovasculaire
ne tiraient  pas  de  bénéﬁce  (ou  avaient  même  un  effet  délétère)  de  l’utilisation  de  nouveaux
traitement  antithrombotiques  plus  puissants,  avec  un  risque  majoré  d’hémorragie  intracrani-
enne. Ce  risque  n’est  cependant  pas  uniforme.  Il  est  plus  élevé  chez  les  patients  avec  un  risque
d’AVC que  chez  ceux  avec  un  risque  d’AIT  et  semble  conﬁné  à  la  1ère année  suivant  l’événement
cérébrovasculaire.  Des  stratégies  spéciﬁques  visant  à  optimiser  la  balance  bénéﬁce/risque  des
traitements  antithrombotiques  dans  ce  sous-groupe  de  patient  relativement  importants  doivent
donc être  développées  et  évaluées.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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lBackground
Atherothrombosis  is  a  generalized  disease  that  often
involves  not  only  the  coronary  arteries,  but  also  other
arterial  beds.  For  that  reason,  patients  presenting  with  sev-
eral  atherothrombosis  locations  are  not  uncommon.  Among
them,  patients  presenting  with  coronary  artery  disease
(CAD)  and  a  history  of  cerebrovascular  disease  are  of  partic-
ular  interest,  because  they  occur  frequently  and  present  a
therapeutic  conundrum.
Patients with CAD and cerebrovascular
disease: a frequent clinical problem
A  history  of  cerebrovascular  disease  (including  stroke  or
transient  ischaemic  attack  [TIA])  is  not  uncommon  in
patients  with  CAD.  In  a  cohort  of  more  than  26,000  patients
with  CAD  enrolled  in  the  REACH  registry  of  atherothrombo-
sis,  4460  patients  (approximately  17%  of  the  CAD  population)
had  a  history  of  cerebrovascular  disease  (stroke  or  TIA)  [1].
In  the  GRACE  registry  of  acute  coronary  syndromes  (ACSs),
patients  with  a  history  of  stroke  constituted  8.25%  of  the
overall  population  [2].  Cerebrovascular  disease  is  there-
fore  a  common  condition  in  patients  with  stable  or  unstable
CAD.
Characteristics of patients with CAD and
cerebrovascular disease
In  the  REACH  registry,  CAD  patients  with  cerebrovascular
disease  were  older,  more  frequently  female  and  more  likely
to  have  a  history  of  diabetes,  hypertension  or  atrial  ﬁbrilla-
tion  than  patients  with  CAD  alone.  Overall,  patients  with
a  history  of  both  CAD  and  cerebrovascular  disease  had  a
higher  baseline  risk  of  recurrent  cardiovascular  and  bleeding
events  [1].
c
t
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bisk of ischaemic events in patients with
AD and cerebrovascular disease
AD  patients  with  a  history  of  cerebrovascular  disease  have
orse  clinical  outcomes  than  patients  without  a  history  of
erebrovascular  disease.  In  the  GRACE  registry,  ACS  patients
ith  a  history  of  stroke  had  dramatically  higher  hospital
nd  6-month  mortality  rates  than  patients  without  a  his-
ory  of  stroke  (8.9%  vs  4.5%  and  9.3%  vs  3.9%,  respectively);
hese  differences  persisted  after  adjustment  for  baseline
haracteristics  [2].  In  a  pooled  analysis  of  ﬁve  French  mul-
icentre  acute  myocardial  infarction  registries,  including
early  10,000  patients  (the  Alliance  project),  multivariable
nalysis  showed  that  a  history  of  cerebrovascular  disease
as  an  independent  factor  for  hospital  mortality  [3].  In  sta-
le  patients,  the  same  observation  was  made  in  the  REACH
egistry:  patients  with  a  history  of  stroke/TIA  had  a  higher
ate  of  5-year  all-cause  death  (17.8%  vs  11.2%)  —  mainly
riven  by  cardiovascular  death  (12.2%  vs  7.1%)  —  and  car-
iovascular  events  (24.9%  vs  13.3%  for  cardiovascular  death,
yocardial  infarction  or  stroke)  —  mainly  driven  by  stroke
13.1%  vs  4.1%)  —  compared  with  patients  with  CAD  alone.
hese  differences  persisted  after  adjustment  for  differences
n  baseline  characteristics  [1].
isk of intracranial haemorrhage in
atients with CAD and cerebrovascular
isease
s  patients  with  CAD  and  previous  stroke/TIA  are  at  higher
isk  of  ischaemic  events,  it  is  tempting  to  increase  the
otency  of  antithrombotic  therapy  in  these  patients.  How-
ver,  in  several  recent  trials  of  new  antithrombotic  agents
uring  or  after  ACS,  patients  with  a  history  of  cerebrovascu-
ar  disease  derived  no  beneﬁt  from  (and  in  some  cases  were
learly  harmed  by)  increasing  the  potency  of  antithrombotic
herapy,  while  the  rest  of  the  patients  (i.e.  patients  with  ACS
ut  without  a  history  of  cerebrovascular  disease)  derived
eneﬁt  (see  Table  1).
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Table  1  Recent  trials  of  new  antithrombotic  agents  in  patients  with  coronary  artery  disease.
Trial  Population  Study  drug  Ischaemic  endpoint  Bleeding  endpoint  Overall
population
Previous
stroke/TIA
Ischaemic
events
Bleeding  events  Ischaemic
events
Bleeding  events
TRACER  ACS  Vorapaxar  Death  from  vascular
cause  +  MI  +  stroke  +
recurrent  ischaemia
with  hospitaliza-
tion  +  urgent  coronary
revascularization
Moderate  or  severe
bleeding  according  to
GUSTO  classiﬁcationa
No  signiﬁcant
reduction  (HR
0.92;  P  =  0.07)
Increased  (HR
1.35;  P  <  0.001);
increase  in  ICH,
1.1%  vs  0.2%
(P  <  0.001)
No  signiﬁcant
interaction
(P  =  0.795)
No  signiﬁcant
interaction
(P  =  0.771)
TRA-2P  Secondary
atherothrom-
bosis
prevention
Vorapaxar  Death  from  vascular
causes  +  MI  +  stroke
Moderate  or  severe
bleeding  according  to
GUSTO  classiﬁcationa
Reduction  (HR
0.87;
P  <  0.001)
Increase  (HR
1.66;  P  <  0.001);
increase  in  ICH,
1%  vs  0.5%
(P  <  0.001)
No  signiﬁcant
interaction
(P  =  0.81)
No  signiﬁcant
interaction
(P  =  0.81)
TRITON  ACS  Prasugrel  Death  from  CV
cause  +  non-fatal
MI  +  non-fatal  stroke
TIMI  major  bleeding  not
related  to  CABG
Reduction  (HR
0.81;
P  <  0.001)
Increase  (HR
1.32;  P  =  0.03)
Increase  (HR
1.37;  P  for
interac-
tion  =  0.02)
Increase  (HR
2.46;  P  for
interac-
tion  =  0.22)
APPRAISE-2  ACS  Apixaban  CV  death  +  MI  +
ischaemic  stroke
TIMI major  bleeding  No  signiﬁcant
reduction  (HR
0.95;  P  =  0.51)
Increased  risk
of  major
bleeding  (HR
2.59;  P  =  0.001)
Trend  toward
worse  outcome
(P  for  interac-
tion  =  0.08)
No  signiﬁcant
interaction
(P  =  0.31)
ATLAS  ACS-2  ACS  Rivaroxaban  CV  death  +  MI  +  stroke  TIMI  major  bleeding  not
related  to  CABG
Reduction  (HR
0.84;
P  =  0.008)
Increase  2.1%  vs
0.6%  (P  <  0.001);
including  ICH,
0.6%  vs  0.2
(P  =  0.009)
No  signiﬁcant
interaction
(P  =  0.10)
Four  events  in
rivaroxaban
group;  none  in
placebo  group
(P  for
interaction  not
possible)
PLATO  ACS  Ticagrelor  CV  death  +  MI  +  stroke  Major  bleeding:  fatal
bleeding  +  ICH
+  intrapericardial  bleeding
with  tamponade  +
haemorrhagic  shock  +
decline  in  Hb  ≥  5  g/dL  +
transfusion  ≥  4  RBC  units
Reduction  (HR
0.84;
P  =  0.001)
No  signiﬁcant
increase
(P =  0.43)
No  signiﬁcant
interaction
(P  =  0.84)
No  signiﬁcant
interaction
(P  =  0.77)
ACS: acute coronary syndrome; CABG: coronary artery bypass graft; CV: cardiovascular; Hb: haemoglobin; HR: hazard ratio; ICH: intracranial haemorrhage; MI: myocardial infarction;
RBC: red blood cell; TIA: transient ischaemic attack; TIMI: thrombolysis in myocardial infarction.
a Therefore includes intracranial bleeding.
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The  TRACER  trial,  evaluating  the  addition  of  vorapaxar
—  a  PAR-1  antagonist  —  to  dual  antiplatelet  therapy  with
aspirin  and  clopidogrel  in  patients  with  ACS,  found  an
increased  risk  of  major  bleeding,  including  ICH  (intracra-
nial  haemorrhage)  [4].  A  subgroup  analysis  showed  a  trend
towards  an  increased  risk  of  bleeding  in  patients  with  a
history  of  stroke.  The  TRA-2P  trial  evaluated  vorapaxar
in  a  secondary  prevention  setting  [5].  In  this  trial,  vora-
paxar  reduced  the  rate  of  the  primary  ischaemic  composite
endpoint  compared  with  placebo,  but  with  a  signiﬁcant
increase  in  bleeding,  including  ICH,  in  patients  with  and
without  a  history  of  stroke.  However,  the  absolute  rate
of  ICH  was  substantially  higher  in  patients  with  a  his-
tory  of  stroke.  Subgroup  analysis  revealed  that,  in  contrast
to  the  overall  population,  there  was  no  beneﬁt  derived
from  adding  vorapaxar  in  the  subgroup  of  patients  with
previous  cerebrovascular  disease.  In  both  of  these  trials,
because  of  an  excess  risk  of  ICH  in  an  interim  analysis,
the  Data  and  Safety  Monitoring  Board  decided  to  with-
hold  treatment  with  vorapaxar  from  patients  with  a  history
of  cerebrovascular  disease.  While  vorapaxar  was  approved
for  secondary  prevention  after  myocardial  infarction,  both
the  Food  and  Drug  Administration  and  the  European
Medicines  Agency  have  designated  history  of  stroke/TIA  as  a
contraindication  [6].
In  the  TRITON-Thrombolysis  in  Myocardial  Infarction
(TIMI)  38  trial,  comparing  prasugrel  with  clopidogrel  in  ACS
patients  treated  with  percutaneous  coronary  intervention,
prasugrel  reduced  the  rate  of  ischaemic  events,  but  at  a
price  (of  an  increased  risk  of  major  bleeding  in  the  over-
all  population)  [7].  However,  a  post-hoc  analysis  identiﬁed
that  patients  with  previous  stroke  or  TIA  derived  net  clinical
harm  from  prasugrel  (hazard  ratio  [HR]  1.54,  95%  conﬁdence
interval  [CI]  1.02  to  2.32;  P  =  0.04),  contrasting  with  the
overall  results  (HR  0.81,  95%  CI  0.73  to  0.90;  P  <  0.001);
this  was  mainly  due  to  excess  bleeding,  including  ICH,  in
this  subgroup.  Moreover,  there  was  a  signiﬁcant  interac-
tion  between  a  history  of  cerebrovascular  events  and  the
net  clinical  beneﬁt  of  prasugrel  over  clopidogrel.  Again,  a
history  of  stroke/TIA  is  a  contraindication  to  prasugrel  treat-
ment  [6].
The  PLATO  trial  demonstrated  a  beneﬁt  for  ticagrelor
versus  clopidogrel  in  ACS  patients  in  terms  of  reducing  the
risk  of  the  primary  composite  ischaemic  outcome  (cardio-
vascular  death,  myocardial  infarction  or  stroke)  [8].  In  the
subgroup  of  patients  with  previous  stroke/TIA,  efﬁcacy  was
consistent  with  that  seen  in  the  overall  trial,  with  even
a  marked  decrease  in  all-cause  mortality  at  1  year  with
ticagrelor  compared  with  clopidogrel  (7.9%  vs  13.0%)  [9].
However,  in  contrast  to  the  increased  risk  seen  in  other  tri-
als,  rates  of  major  bleeding  —  according  to  the  PLATO  or
TIMI  deﬁnitions  —  were  not  increased  with  ticagrelor  com-
pared  to  clopidogrel.  Note,  however,  that  there  were  too
few  ICHs  to  deﬁnitively  rule  out  an  increase  in  the  risk  of
ICH  with  ticagrelor  [10].  In  addition,  in  the  overall  trial
population,  there  was  a  trend  toward  more  ICH  with  tica-
grelor  than  with  clopidogrel  (0.3%  vs  0.2%;  P  =  0.06).  The
SOCRATES  trial  (ClinicalTrials.gov  identiﬁer  NCT01994720)
will  compare  ticagrelor  initiated  within  24  hours  after  stroke
or  high-risk  TIA  onset  with  aspirin;  it  will  provide  important
information  on  the  safety  of  ticagrelor  in  the  early  weeks
following  stroke  or  TIA  [11].
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The  APPRAISE-2  trial,  evaluating  a  high  dose  (5  mg  twice
aily)  of  apixaban,  a  factor  Xa  inhibitor,  in  addition  to
tandard  therapy  after  recent  ACS,  was  terminated  pre-
aturely  because  of  an  increase  in  major  bleeding  events
ith  apixaban  without  a  signiﬁcant  reduction  in  recurrent
schaemic  events  [12].  In  patients  with  previous  stroke,  apix-
ban  was  associated  with  worse  outcomes  regarding  the
rimary  efﬁcacy  endpoint  (P  for  interaction  =  0.08)  and  an
ncrease  in  TIMI  major  bleeding,  although  this  was  not  sig-
iﬁcant  (HR  5.44  for  patients  with  previous  stroke  vs  2.27
or  patients  without;  P  for  interaction  =  0.31).
Rivaroxaban,  another  factor  Xa  inhibitor,  was  evaluated
n  top  of  dual  antiplatelet  therapy  in  the  ATLAS  ACS-2  trial
13]. In  this  trial,  which  included  15,526  patients  with  a
ecent  ACS,  a  low  dose  of  rivaroxaban  (2.5  mg  or  5  mg  twice
aily)  reduced  the  risk  of  the  primary  composite  endpoint
8.9%  vs  10.7%,  HR  0.84,  95%  CI  0.74  to  0.96;  P  =  0.008),  but
ncreased  the  risk  of  major  bleeding  (2.1%  vs  0.6%;  P  <  0.001)
nd  ICH  (0.6%  vs  0.2%;  P  = 0.009)  in  the  overall  trial  popu-
ation.  There  were  too  few  bleeding  events  in  the  subgroup
f  patients  with  a  history  of  stroke/TIA  (four  events  in  the
ivaroxaban  arm;  none  in  the  placebo  arm)  to  allow  a  mean-
ngful  comparison.
This  increased  risk  of  ICH  in  patients  with  CAD  and  a  his-
ory  of  stroke  was  also  seen  in  observational  studies,  such
s  the  REACH  registry  [1].  In  this  registry,  patients  with  CAD
nd  a  history  of  stroke  had  a  higher  risk  of  ICH  (adjusted
R  for  non-fatal  haemorrhagic  stroke  1.76,  95%  CI  1.00  to
.08;  P  =  0.05).  When  the  analysis  was  stratiﬁed  according  to
ntiplatelet  therapy  at  admission,  the  increased  risk  of  non-
atal  haemorrhagic  stroke  was  particularly  high  in  patients
eceiving  dual  antiplatelet  therapy.  In  this  subgroup,  the
djusted  HR  of  non-fatal  haemorrhagic  stroke  associated
ith  cerebrovascular  disease  history  was  5.21  (95%  CI  1.24  to
1.90),  whereas  there  was  no  signiﬁcant  increase  in  patients
eceiving  no  or  single  antiplatelet  therapy.
Patients  with  CAD  and  a  history  of  cerebrovascular  dis-
ase  therefore  have  a  high  risk  of  recurrent  ischaemic
vents.  However,  there  is  a consistent  pattern  across  trials  —
ith  the  possible  exception  of  ticagrelor  in  the  PLATO  trial
 of  a  disproportionate  increase  in  ICH  when  the  potency  of
ntithrombotic  therapy  is  increased.
he risk of ICH is not uniform in all
atients  with cerebrovascular disease
he  increase  in  bleeding  risk  does  not  appear  to  be  uniform
cross  all  patients  with  cerebrovascular  disease.  An  analysis
rom  the  REACH  registry  demonstrated  that  patients  with
AD  and  a  history  of  stroke  had  a  higher  risk  of  ICH.  The
ensitivity  analysis,  excluding  patients  with  TIA  only,  made
 similar  observation  in  patients  with  a  history  of  stroke
nly.  Conversely,  patients  with  a  history  of  TIA  alone  had
 lower  increase  in  stroke  rate  and  no  difference  in  death
ate.  It  appears,  therefore,  that  the  risk  of  ICH  is  greater
or  patients  with  a  history  of  stroke  than  for  those  with  a
istory  of  TIA  [1].
The  risk  of  ICH  also  varies  according  to  the  time  elapsed
ince  a  previous  stroke/TIA.  In  the  REACH  registry  [1],  the
xcess  risk  of  non-fatal  haemorrhagic  stroke  in  patients  with
610  G.  Ducrocq,  P.G.  Steg
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Rigure 1. Proposed algorithm for antithrombotic medications in a
 history  of  stroke/TIA  compared  with  in  those  without  a  his-
ory  of  stroke/TIA  decreased  with  the  time  elapsed  between
erebrovascular  disease  onset  and  enrolment.  The  increased
isk  appeared  to  be  conﬁned  to  the  ﬁrst  year  following
 stroke  or  TIA  (adjusted  HR  3.03,  95%  CI  1.51  to  6.08),
hereas  beyond  1  year,  the  risk  was  not  increased  (adjusted
R  1.15,  95%  CI  0.53  to  2.47).  Overall,  the  risk  of  haemor-
hagic  stroke  was  greater  in  the  ﬁrst  year  after  a  stroke/TIA
han  later  (HR  2.64,  95%  CI  1.04  to  6.69;  P  =  0.041).
To  take  into  account  these  differences  in  ICH  risk,  we
ave  proposed  an  algorithm  for  ACS  patients  (Fig.  1).
n  patients  without  a  history  of  stroke/TIA,  we  suggest
icagrelor  or  prasugrel  as  ﬁrst-line  therapy,  in  agreement
ith  the  European  Society  of  Cardiology  guidelines  [14].  In
atients  with  a  history  of  stroke/TIA,  prasugrel  is  contraindi-
ated  [7].  Based  on  the  results  of  the  REACH  registry  analysis
1],  and  the  mortality  beneﬁt  provided  by  ticagrelor  com-
ared  with  clopidogrel  in  this  population  [9],  we  suggest
sing  ticagrelor  as  ﬁrst-line  therapy  in  patients  with  a  history
f  stroke/TIA  >  1  year  previously.  In  patients  with  a  history
f  stroke  within  the  previous  year,  based  on  the  results  of
he  REACH  analysis,  we  suggest  using  clopidogrel  as  ﬁrst-line
herapy  until  additional  information  about  ticagrelor  safety
ecomes  available  [11].onclusions
atients  with  CAD  and  a  history  of  stroke  are  a  relatively
arge  patient  subset  (accounting  for  as  many  as  8—17%  of coronary syndrome patients. TIA: transient ischaemic attack.
AD  patients).  These  patients  are  at  higher  risk  of  ischaemic
vents,  but  also  ICH.  In  this  population,  increasing  the
otency  of  antithrombotic  treatment  is  generally  associ-
ted  with  an  increased  risk  of  ICH.  However,  the  increase  in
leeding  risk  does  not  appear  to  be  uniform  in  all  patients
ith  cerebrovascular  disease:  it  is  greater  for  patients  with
 history  of  stroke  (compared  with  a history  of  TIA),  and  in
he  ﬁrst  year  after  stroke.  Speciﬁc  strategies  to  optimize  the
anagement  of  this  group  of  patients  should  be  developed
nd  evaluated.
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